Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, discusses how practices and administrators can build higher pathway compliance

Published: 13 February 2017

Recent Videos

video

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, ...

video

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, on whether physicians will adopt the Leukostat test, which was ...

video

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, speculates on the future of immunotherapy combinations when treating small ...

video

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, elaborates on the challenges associated with biomarkers when treating small ...

video

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, describes how immunotherapies should be integrated into the treatment of ...

video

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, elaborates on the effectiveness of CAR T-cell therapy in treating multiple ...

video

Patricia Goldsmith describes new patient-focused initiatives presented at ASCO 2017

Patricia Goldsmith, CEO, Cancer Care, regarding new information on patient-focused initiatives coming out of ASCO 2017

video

Richard Goldberg, MD, FASCO, on the new FDA indication for pembrolizumab

Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, provides opinion on the new FDA indication for pembrolizumab in tumor-agnostic ...

video

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, on adopting vemurafenib in BRAF+ mutation ...

video

Barbara Burtness, MD, on bevacizumab and chemotherapy for treatment of metastatic H&C cancers

Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, ...

Related Videos

video-image

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

video-image

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

video-image

Patricia Goldsmith describes new patient-focused initiatives presented at ASCO 2017

video-image

Richard Goldberg, MD, FASCO, on the new FDA indication for pembrolizumab

video-image

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

video-image

Barbara Burtness, MD, on bevacizumab and chemotherapy for treatment of metastatic H&C cancers

video-image

David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients

video-image

Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients

video-image

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients

video-image

Nancy Dawson, MD, shares her impressions of the LATITUDE study

video-image

Nancy Dawson, MD, regarding the STAMPEDE study presented at ASCO 2017

video-image

Thaddeus Beck, MD, FACP, shares his experience working with Watson for Clinical Trials Matching

video-image

Christopher Logothetis, MD, offers opinion on the efficacy of the AR-V7 test

video-image

Jeffrey Meyerhardt, MD, offers opinion on the effectiveness of SIRT in treatment of metastatic HCC

video-image

Barbara Burtness, MD, considers whether H&N patients should be routinely tested for PD-L1

video-image

Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer